Literature DB >> 16103011

Artificial antigen-presenting cells: artificial solutions for real diseases.

Mathias Oelke1, Christine Krueger, Robert L Giuntoli, Jonathan P Schneck.   

Abstract

Adoptive immunotherapy, which involves the transfer of autologous antigen-specific T cells generated ex vivo, is a promising strategy to treat a variety of life-threatening diseases. Unfortunately, current approaches for generating sufficient numbers of antigen-specific T cells lack the ability to serve as reproducible and economically viable methods. This has spurred the development of both cell- and non-cell-based artificial antigen-presenting cells to alleviate problems associated with peptide-loaded dendritic cells in current approaches to adoptive immunotherapy. Here, we review new strategies for the ex vivo generation of antigen-specific T cells and their clinical application. These new approaches have the potential to spearhead a new era of successful adoptive immunotherapy for cancer and infectious diseases.

Entities:  

Mesh:

Year:  2005        PMID: 16103011     DOI: 10.1016/j.molmed.2005.07.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  13 in total

1.  High-throughput engineering and analysis of peptide binding to class II MHC.

Authors:  Wei Jiang; Eric T Boder
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-09       Impact factor: 11.205

Review 2.  Nanoscale artificial antigen presenting cells for cancer immunotherapy.

Authors:  Kelly R Rhodes; Jordan J Green
Journal:  Mol Immunol       Date:  2018-03-07       Impact factor: 4.407

3.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

Review 4.  Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 5.  Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy.

Authors:  Matjaz Jeras; Irena Bricl; Robert Zorec; Urban Svajger
Journal:  J Biomed Biotechnol       Date:  2010-03-10

6.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Authors:  Stefano Ugel; Alessia Zoso; Carmela De Santo; Yu Li; Ilaria Marigo; Paola Zanovello; Elisa Scarselli; Barbara Cipriani; Mathias Oelke; Jonathan P Schneck; Vincenzo Bronte
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 7.  Biomimetic particles as therapeutics.

Authors:  Randall A Meyer; Joel C Sunshine; Jordan J Green
Journal:  Trends Biotechnol       Date:  2015-08-12       Impact factor: 19.536

Review 8.  Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design.

Authors:  Randall A Meyer; Jordan J Green
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-05-15

9.  HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.

Authors:  Yen-Ling Chiu; Jonathan P Schneck; Mathias Oelke
Journal:  J Vis Exp       Date:  2011-04-11       Impact factor: 1.355

10.  T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs.

Authors:  Andréa Barbosa de Melo; Eduardo J M Nascimento; Ulisses Braga-Neto; Rafael Dhalia; Ana Maria Silva; Mathias Oelke; Jonathan P Schneck; John Sidney; Alessandro Sette; Silvia M L Montenegro; Ernesto T A Marques
Journal:  PLoS Negl Trop Dis       Date:  2013-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.